Black and Hispanic patients with MCC are more likely to have tumors on UV-protected sites, which is associated with better outcomes.

Concomitant IBD reduces disease control and treatment response among patients with PsA receiving biologic therapy.

Ixekizumab was more effective for the treatment of mild to moderate psoriasis vs severe psoriasis at most time points through 52 weeks.

In both studies, upadacitinib met the coprimary endpoints of T-VASI 50 and F-VASI 75 at week 48 vs placebo. Topline data were announced from 2 replicate phase 3 studies evaluating upadacitinib in ...

The FDA said fluoride should not be routinely prescribed, but the American Dental Association still recommends prescription fluoride for children at high risk for tooth decay. HealthDay News — The U.S ...

A family history of malignancy is the only patient-specific factor associated with a significantly increased risk for cancer among patients with psoriatic disease treated with biologics vs topical ...

Despite having greater rates of cardiometabolic risk factors and atherosclerotic cardiovascular disease risk, less than a quarter of patients with severe hidradenitis suppurativa are meeting treatment ...

The drugs, including potential new treatments for vaping addiction, deafness, pancreatic cancer and other serious health conditions, will go through the approval process in 1 to 2 months rather than ...

DermaRite is instructing distributors and customers to examine their inventory and destroy all affected products. DermaRite Industries, LLC is recalling multiple products, including antiseptic lotion ...

Though not yet approved by the Food and Drug Administration, oral dutasteride 0.5 mg daily was the most effective monotherapy regimen among the 18 regimens studied for the treatment of androgenetic ...

Patients with port-wine stains treated with hemoporfin-mediated photodynamic therapy experience changes to the surface roughness, roughness depth, and mean square roughness of their skin.

At 12 weeks after changing biologic therapies, 69.0% of patients who switched intraclass achieved PASI 75, compared with 35.3% of patients who switched interclass. For patients with plaque psoriasis ...